We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo MEDLAB 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bio-Rad to Acquire Digital PCR Developer Stilla Technologies

By LabMedica International staff writers
Posted on 14 Feb 2025

Bio-Rad Laboratories (Hercules, CA, USA) has entered into a binding offer to purchase all equity interests in Stilla Technologies (Villejuif, France). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.

With operations in France and the U.S., Stilla develops and markets next-generation digital PCR instruments, consumables, and assays. The company’s Nio family of all-in-one digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing.


Image: The Nio family of all-in-one digital PCR systems complements Bio-Rad’s existing digital PCR portfolio (Photo courtesy of Stilla)
Image: The Nio family of all-in-one digital PCR systems complements Bio-Rad’s existing digital PCR portfolio (Photo courtesy of Stilla)

"Stilla’s next-generation digital PCR solutions would make a compelling and complementary addition to Bio-Rad’s best-in-class digital PCR portfolio,” said Norman Schwartz, CEO of Bio-Rad Laboratories. “Once closed, the acquisition will support our strategy to further expand our business into applied research and clinical diagnostics where customers expect a higher degree of automation and throughput capabilities.”

“Together with our planned launch of Bio-Rad’s QX Continuum system, the Stilla platform would allow us to serve the full range of digital PCR applications and help us meet the evolving needs of customers in genomics research and applied science,” added Jim Barry, EVP and President of Bio-Rad’s Life Science Group.

“We are thrilled with the prospect of joining Bio-Rad, a leader in the field of digital PCR,” stated Rémi Dangla, CEO of Stilla Technologies. “With Stilla’s passion for product development and Bio-Rad’s extensive life science expertise, operational excellence, and global reach, together we can bring substantial value to the work of applied research and biopharma customers around the globe.”

Related Links:
Bio-Rad Laboratories
Stilla Technologies


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Cytomegalovirus Assay
Alethia CMV
New
Microplates
Eppendorf Microplates

Latest Industry News

ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio

Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business

New Partnership Revolutionizes Analyses of Biological Samples